Meclizine Hydrochloride

Melizin tablet is indicated for the management of nausea and vomiting, and dizziness associated with motion sickness, vertigo associated with diseases affecting the vestibular system.

Meclizine has antiemetic, anticholinergic and antihistaminic properties. It reduces the sensitivity of the labyrinthine apparatus. The action may be mediated through nerve pathways to the vomiting center (VC) from the chemoreceptor trigger zone (CTZ), peripheral nerve pathways, the VC, or other CNS centers. Meclizine has an onset of action of 30 to 60 minutes, depending on dosage; their duration of action is 12 to 24 hours.

For the prevention and treatment of nausea, vomiting and vertigo associated with motion sickness, the usual oral dosage of meclizine hydrochloride in adults and children 12 years of age or older is 25-50 mg once daily. Vertigo : for the control of vertigo associated with diseases affecting the vestibular system, the recommended dose is 25 to 100mg daily, in divided doses, depending upon clinical response. Motion Sickness : The initial dose of 25 to 50mg should be taken one hour prior to embarkation for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

Additive CNS depression may occur where Melizin are administered concomitantly with other CNS depressants including barbiturates, tranquilizers and alcohol.

Meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.

Pregnancy Category B by FDA. Safety for use in the nursing mother has not been established.

Due to its potential anticholinergic action, Melizin should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.

Store in a cool & dry place and away from children.